Healthcare Provider Administration of Biologics for Patients with Plaque Psoriasis: Literature Review and Clinical Considerations JCAD The Journal of Clinical and Aesthetic Dermatology Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvementespecially Real World Canadian Case Series: Use of Tildrakizumab for Moderate to Severe Psoriasis Advances in psoriasis research: From pathogenesis to therapeutics ScienceDirect